Dr. José Mangione Inaugurated as New SOLACI President

Dr. José Mangione, renowned Latin American interventional cardiologist of ample trajectory, is now in charge of the Latin American Interventional Cardiology’s destiny for the next two years, following Dr. José Luis Leiva Pons’ (Mexico) successful administration.

Dr. José Mangione will preside SOLACI during the term 2019-2021. PH: Antônio More / MorePress.

“I am honored and delighted to take this responsibility”, stated Dr. Mangione during the closing ceremony of SOLACI-SBHCI 2019. And added: “SOLACI has been conducted by many of the great names of Latin American Interventional Cardiology. SOLACI is a strong notable brand with a solid reputation around the world. My job will be to keep uniting cardiovascular intervention across the region.

Trained at Mogi das Cruzes University, Dr. Mangione is the former President of the Brazilian Society of Hemodynamics and Interventional Cardiology (SHBCI) in addition to having been the former Vice-President to Dr. Leiva Pons at SOLACI. Thus, he certainly knows the ropes of our society.

His first words as president emphasized the importance of hard work in the scientific area at SOLACI: “My concern, responsibility and determination is to further develop the scientific part of SOLACI, (…) we must continue working with our local societies in depth to show the world that Latin America is capable of world class interventionism”..

Dr. Leiva Pons bid farewell to SOLACI Presidency. PH: Antônio More / MorePress.

Dr. Mangione will be assisted as Vice President by Dr. Anibal Damonte, current President of the Argentinian School of Interventional Cardiologists (CACI) and founding member of SOLACI. Dr. Alfaro Marchena Noriega (Panama) will continue to be the Secretary and Dr. Omar Santaera (Argentina) will continue as our institution’s Treasurer.

On the other hand, during the closing ceremony Dr. José Luis Leiva Pons pointed out the success of SOLACI-SBHCI 2019 (“An event with excellent attendance and the presence of international professors of the highest category”), he thanked the authorities (Dra. Viviana Lemke, President of SBHCI, and Dr. Alexandre Schaan of Quadros, President of the event’s Scientific Commettee) and praised the work done throughout the year: “we have worked hard to get where we are and are extremely pleased with the result. We are grateful for the presence of you all”.

He finally said goodbye: “We leave SOLACI in great hands. See you at Buenos Aires 2020”..


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

ACC 2026: SURViV Trial Results – Exclusive Presentation and Analysis with Dr. Dimytri Siqueira

Following the presentation of the SURViV trial in the Late Breaking Clinical Trials sessions at the American College of Cardiology Congress, Dr. Dimytri Siqueira...

Embolization of Left Atrial Appendage Closure Devices: Predictors, Prevention, and Management Strategies

Atrial fibrillation is associated with an increased risk of stroke and, in patients with contraindications to anticoagulation, percutaneous left atrial appendage closure represents an...

SOLACI Technicians Webinar – Ultrasound Pulses + Calcium = Coronary Lithotripsy

The Latin American Society of Interventional Cardiology (SOLACI) invites you to participate in a new Live SOLACI Webinar specially designed for technicians, nurses, and...

Coronary revascularization before TAVI: prior PCI or conservative management?

The coexistence of coronary artery disease (CAD) in patients with severe aortic stenosis undergoing TAVI is common, with a reported prevalence ranging from 30%...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACC 2026 | CHIP-BCIS3: Impella use as support in high-risk complex PCI

The use of percutaneous ventricular support during high-risk complex PCI has been proposed as a strategy to prevent hemodynamic deterioration in patients with severe...

ACC 2026 | ORBITA-CTO: PCI in chronic total occlusions and stable angina — the randomized trial we were missing?

Percutaneous coronary intervention (PCI) for chronic total occlusions (CTO) remains a topic of ongoing debate in stable angina, with persistent uncertainty regarding its role...

ACC 2026 | FAST III: vFFR vs FFR in physiology-guided revascularization of intermediate coronary lesions

Physiological assessment of intermediate coronary lesions remains a cornerstone in decision-making for coronary revascularization. Although FFR continues to be one of the guideline-recommended references,...